Results of recent studies have shown that blood pressure control is achieved in less than
half of hypertensive patients taking currently available antihypertensive agents [1–3]. Given …

Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively
studied in the Bristol-Myers Squibb/Sanofi clinical development program. As shown in seven …

Synopsis Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective non-
competitive antagonism of the AII receptor subtype I (AT 1) which mediates most of the …

This article reviews the pharmacokinetics and pharmacodynamics of angiotensin II (AII)
receptor antagonists (AIIRA), with particular focus on the novel compound irbesartan …

This study compared the efficacy and tolerability of two dose-titrated regimens of irbesartan,
an angiotensin II receptor antagonist selective for the AT 1 subtype, vs placebo in …

Two multicenter, double-blind, placebo-controlled, parallel group studies were conducted to
evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of the angiotensin II …

The recently developed and marketed angiotensin II type 1 (AT1) receptor blockers (ARBs)
have demonstrated efficacy equivalent to that of other leading classes of antihypertensive …

We studied the hemodynamic, neurohumoral, and biochemical effects of the novel
angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with …

The renin-angiotensin system (RAS) plays a key role in regulating blood pressure (BP) and
fluid and electrolyte balance in the body. Strategies to inhibit the RAS have been achieved …

Abstract The angiotensin II (Ang II) receptor antagonists are the most selective blockers of
the renin-angiotensin system (RAS) currently available. The efficacy of these drugs is similar …